Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression

Yutaka Kawakami, Siona Eliyahu, Christopher Jennings, Kazuyasu Sakaguchi, Xiaoqiang Kang, Scott Southwood, Paul F. Robbins, Alessandro Sette, Ettore Appella, Steven A. Rosenberg

Research output: Contribution to journalArticle

501 Citations (Scopus)

Abstract

Four often HLA-A2-restricted melanoma specific CTL that were derived from tumor-infiltrating lymphocytes (TIL) and administered to patients recognized the gp100 melanoma Ag and nine of ten recognized the MART-1 Ag. Adoptive transfer of the four gp100-reactive CTL, but not the other TIL, resulted in tumor regression when infused into autologous patients along with IL-2. Tumor regression was thus correlated with the recognition of gp100 by the administered T cells (p = 0.0048). To identify the epitopes recognized by these four gp100-reactive CTL, 169 peptides containing HLA-A2.1 binding motifs were synthesized and screened for their recognition by TIL using cytotoxicity and IFN-γ release assays. Five gp100 epitopes (two for TIL620, three for TIL660, one for TIL1143, and two for TIL1200) were recognized by CTL derived from different patients. Five of eight HLA-A2 binding melanoma epitopes (five gpl 00, one MART-1/Melan-A, two tyrosinase) had intermediate binding affinity to HLA-A2.1. These gp100 epitopes may be responsible for mediating tumor rejection in vivo and thus may be useful for the devel opment of immunotherapies for patients with melanoma.

Original languageEnglish
Pages (from-to)3969-3974
Number of pages6
JournalJournal of Immunology
Volume154
Issue number8
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

gp100 Melanoma Antigen
Tumor-Infiltrating Lymphocytes
Epitopes
Melanoma
T-Lymphocytes
HLA-A2 Antigen
Neoplasms
MART-1 Antigen
Monophenol Monooxygenase
Adoptive Transfer
Immunotherapy
Interleukin-2
Peptides

ASJC Scopus subject areas

  • Immunology

Cite this

Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., ... Rosenberg, S. A. (1995). Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. Journal of Immunology, 154(8), 3969-3974.

Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. / Kawakami, Yutaka; Eliyahu, Siona; Jennings, Christopher; Sakaguchi, Kazuyasu; Kang, Xiaoqiang; Southwood, Scott; Robbins, Paul F.; Sette, Alessandro; Appella, Ettore; Rosenberg, Steven A.

In: Journal of Immunology, Vol. 154, No. 8, 1995, p. 3969-3974.

Research output: Contribution to journalArticle

Kawakami, Y, Eliyahu, S, Jennings, C, Sakaguchi, K, Kang, X, Southwood, S, Robbins, PF, Sette, A, Appella, E & Rosenberg, SA 1995, 'Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression', Journal of Immunology, vol. 154, no. 8, pp. 3969-3974.
Kawakami, Yutaka ; Eliyahu, Siona ; Jennings, Christopher ; Sakaguchi, Kazuyasu ; Kang, Xiaoqiang ; Southwood, Scott ; Robbins, Paul F. ; Sette, Alessandro ; Appella, Ettore ; Rosenberg, Steven A. / Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. In: Journal of Immunology. 1995 ; Vol. 154, No. 8. pp. 3969-3974.
@article{645f8846b9ae4967a9262a1129f4d05c,
title = "Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression",
abstract = "Four often HLA-A2-restricted melanoma specific CTL that were derived from tumor-infiltrating lymphocytes (TIL) and administered to patients recognized the gp100 melanoma Ag and nine of ten recognized the MART-1 Ag. Adoptive transfer of the four gp100-reactive CTL, but not the other TIL, resulted in tumor regression when infused into autologous patients along with IL-2. Tumor regression was thus correlated with the recognition of gp100 by the administered T cells (p = 0.0048). To identify the epitopes recognized by these four gp100-reactive CTL, 169 peptides containing HLA-A2.1 binding motifs were synthesized and screened for their recognition by TIL using cytotoxicity and IFN-γ release assays. Five gp100 epitopes (two for TIL620, three for TIL660, one for TIL1143, and two for TIL1200) were recognized by CTL derived from different patients. Five of eight HLA-A2 binding melanoma epitopes (five gpl 00, one MART-1/Melan-A, two tyrosinase) had intermediate binding affinity to HLA-A2.1. These gp100 epitopes may be responsible for mediating tumor rejection in vivo and thus may be useful for the devel opment of immunotherapies for patients with melanoma.",
author = "Yutaka Kawakami and Siona Eliyahu and Christopher Jennings and Kazuyasu Sakaguchi and Xiaoqiang Kang and Scott Southwood and Robbins, {Paul F.} and Alessandro Sette and Ettore Appella and Rosenberg, {Steven A.}",
year = "1995",
language = "English",
volume = "154",
pages = "3969--3974",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "8",

}

TY - JOUR

T1 - Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression

AU - Kawakami, Yutaka

AU - Eliyahu, Siona

AU - Jennings, Christopher

AU - Sakaguchi, Kazuyasu

AU - Kang, Xiaoqiang

AU - Southwood, Scott

AU - Robbins, Paul F.

AU - Sette, Alessandro

AU - Appella, Ettore

AU - Rosenberg, Steven A.

PY - 1995

Y1 - 1995

N2 - Four often HLA-A2-restricted melanoma specific CTL that were derived from tumor-infiltrating lymphocytes (TIL) and administered to patients recognized the gp100 melanoma Ag and nine of ten recognized the MART-1 Ag. Adoptive transfer of the four gp100-reactive CTL, but not the other TIL, resulted in tumor regression when infused into autologous patients along with IL-2. Tumor regression was thus correlated with the recognition of gp100 by the administered T cells (p = 0.0048). To identify the epitopes recognized by these four gp100-reactive CTL, 169 peptides containing HLA-A2.1 binding motifs were synthesized and screened for their recognition by TIL using cytotoxicity and IFN-γ release assays. Five gp100 epitopes (two for TIL620, three for TIL660, one for TIL1143, and two for TIL1200) were recognized by CTL derived from different patients. Five of eight HLA-A2 binding melanoma epitopes (five gpl 00, one MART-1/Melan-A, two tyrosinase) had intermediate binding affinity to HLA-A2.1. These gp100 epitopes may be responsible for mediating tumor rejection in vivo and thus may be useful for the devel opment of immunotherapies for patients with melanoma.

AB - Four often HLA-A2-restricted melanoma specific CTL that were derived from tumor-infiltrating lymphocytes (TIL) and administered to patients recognized the gp100 melanoma Ag and nine of ten recognized the MART-1 Ag. Adoptive transfer of the four gp100-reactive CTL, but not the other TIL, resulted in tumor regression when infused into autologous patients along with IL-2. Tumor regression was thus correlated with the recognition of gp100 by the administered T cells (p = 0.0048). To identify the epitopes recognized by these four gp100-reactive CTL, 169 peptides containing HLA-A2.1 binding motifs were synthesized and screened for their recognition by TIL using cytotoxicity and IFN-γ release assays. Five gp100 epitopes (two for TIL620, three for TIL660, one for TIL1143, and two for TIL1200) were recognized by CTL derived from different patients. Five of eight HLA-A2 binding melanoma epitopes (five gpl 00, one MART-1/Melan-A, two tyrosinase) had intermediate binding affinity to HLA-A2.1. These gp100 epitopes may be responsible for mediating tumor rejection in vivo and thus may be useful for the devel opment of immunotherapies for patients with melanoma.

UR - http://www.scopus.com/inward/record.url?scp=14844341146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844341146&partnerID=8YFLogxK

M3 - Article

VL - 154

SP - 3969

EP - 3974

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 8

ER -